{"id":754076,"date":"2025-07-28T17:26:01","date_gmt":"2025-07-28T17:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=754076"},"modified":"2025-07-28T17:26:01","modified_gmt":"2025-07-28T17:26:01","slug":"myelodysplastic-syndrome-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-novartis-syros-pharmaceuticals-curis-ryvu-therapeutics-chia-tai-tia","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myelodysplastic-syndrome-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-novartis-syros-pharmaceuticals-curis-ryvu-therapeutics-chia-tai-tia_754076.html","title":{"rendered":"Myelodysplastic Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tia"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/07\/1753702947.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Myelodysplastic Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tia\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/07\/1753702947.jpg\" alt=\"Myelodysplastic Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tia\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Myelodysplastic Syndrome Pipeline Insight, 2025<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cMyelodysplastic Syndrome &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">According to DelveInsight, over 120 key companies are actively engaged in the development of more than 125 therapeutic candidates targeting Myelodysplastic Syndrome.<\/p>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Myelodysplastic syndrome (MDS) encompasses a group of complex blood disorders marked by the abnormal maturation of hematopoietic stem cells, leading to ineffective production of blood cells in the bone marrow. In some cases, MDS can evolve into acute myeloid leukemia (AML). The condition primarily affects individuals over the age of 65 and is typically associated with low counts of red blood cells, white blood cells, and platelets. The disease progression can vary significantly among patients.<\/p>\n<p style=\"text-align: justify;\">Several factors can contribute to the development of MDS, including exposure to environmental toxins like benzene, radiation, and prior chemotherapy. However, in many older adults, the exact cause is often unclear. Furthermore, inherited or acquired bone marrow failure syndromes, such as Fanconi anemia and aplastic anemia, can increase susceptibility to MDS and may share overlapping clinical features.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a detailed insights report on Myelodysplastic Syndrome pipeline insights @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Myelodysplastic Syndrome Pipeline Insight 2025&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Myelodysplastic Syndrome Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Myelodysplastic Syndrome treatment.<\/p>\n<\/li>\n<li>\n<p>In January 2025, Keros Therapeutics Inc. initiated a clinical trial (KER-050-D301) to assess the efficacy and safety of elritercept (KER-050) compared to a placebo in adults with transfusion-dependent anemia associated with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS), now classified as myelodysplastic neoplasms. The study includes multiple phases: a Screening Period, a Double-Blind Treatment Period, a Safety Follow-Up Period, and a Long-Term Follow-Up Period.<\/p>\n<\/li>\n<li>\n<p>Meanwhile, Bristol-Myers Squibb launched a study to evaluate the effectiveness and safety of Luspatercept versus epoxetin alfa in treating anemia in adults with very low, low, or intermediate-risk MDS (as per IPSS-R criteria). This trial focuses on ESA-na&iuml;ve patients who are non-transfusion dependent (NTD).<\/p>\n<\/li>\n<li>\n<p>Key Myelodysplastic Syndrome companies such as Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others are evaluating new drugs for Myelodysplastic Syndrome to improve the treatment landscape.<\/p>\n<\/li>\n<li>\n<p>Promising Myelodysplastic Syndrome pipeline therapies in various stages of development include Tamibarotene, CA-4948, RVU120, MNV-201, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights into the key companies that are developing therapies in the Myelodysplastic Syndrome Market.<\/p>\n<\/li>\n<li>\n<p>The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome treatment.<\/p>\n<\/li>\n<li>\n<p>It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Myelodysplastic Syndrome market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download our free sample page report on Myelodysplastic Syndrome pipeline insights @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Tamibarotene: Syros Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>CA-4948: Curis<\/p>\n<\/li>\n<li>\n<p>RVU120: Ryvu Therapeutics<\/p>\n<\/li>\n<li>\n<p>MNV-201: Minovia Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Approximately 120 leading companies are currently engaged in developing treatments for Myelodysplastic Syndrome. Among these, Syros Pharmaceuticals stands out with a drug candidate that has reached the most advanced stage&mdash;Phase III of clinical development.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 125+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Myelodysplastic Syndrome Therapies and Key Companies: Myelodysplastic Syndrome Clinical Trials and advancements @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myelodysplastic Syndrome Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Myelodysplastic Syndrome Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">&bull; Myelodysplastic Syndrome By Stage<\/p>\n<p style=\"text-align: justify;\">&bull; Myelodysplastic Syndrome Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">&bull; Myelodysplastic Syndrome Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\"><strong>Download Myelodysplastic Syndrome Sample report to know in detail about the Myelodysplastic Syndrome treatment market @ Myelodysplastic Syndrome Therapeutic Assessment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Myelodysplastic Syndrome Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Myelodysplastic Syndrome &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Myelodysplastic Syndrome Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Myelodysplastic Syndrome Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Myelodysplastic Syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Myelodysplastic Syndrome Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Myelodysplastic Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Myelodysplastic Syndrome Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Myelodysplastic Syndrome Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get Detailed Insights About the Myelodysplastic Syndrome Pipeline Reports Offerings: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=myelodysplastic-syndrome-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-novartis-syros-pharmaceuticals-curis-ryvu-therapeutics-chia-tai-tia\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=myelodysplastic-syndrome-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-novartis-syros-pharmaceuticals-curis-ryvu-therapeutics-chia-tai-tia\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Myelodysplastic Syndrome Pipeline Insight, 2025 DelveInsight\u2019s, \u201cMyelodysplastic Syndrome &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/myelodysplastic-syndrome-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-novartis-syros-pharmaceuticals-curis-ryvu-therapeutics-chia-tai-tia_754076.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-754076","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/754076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=754076"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/754076\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=754076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=754076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=754076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}